Current development
PRAM
Ultra-sensitive, amplification-free diagnostic platform under development for oncology and infectious-disease applications.
DevelopmentPipeline
A controlled development roadmap for accessible diagnostics.
GNGBM communicates development direction without publishing confidential engineering milestones, assay performance data or unapproved timelines.
Current development
PRAM Mini
A portable version of PRAM intended to support decentralized and point-of-care-ready testing environments.
FeasibilityAssay development direction
Oncology assays
Selected liquid-biopsy and biomarker applications progressing through research and development.
ResearchAssay development direction
Infectious-disease assays
Selected syndrome- and pathogen-oriented applications being assessed for progression toward practical diagnostic assays.
EvaluationFuture direction
Accessible diagnostic deployment
Future exploration includes multiplex assay expansion, decentralized laboratory deployment, AI-assisted interpretation and accessible testing for Tier 1, Tier 2 and Tier 3 India.
Future